PDL BioPharma, Inc.

Historical 13F Holders

Symbol
PDLI
CUSIP
69329Y104
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 69329Y104 since 12/18/2024, largest first.

Filer % of Class Filed
Brandes Investment Partners, LP 13G 6.2% 8/13/2026
Event 6/30/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 6 54.4 k $29.2 k
2026 Q1 7 54.5 k $29.2 k
2025 Q4 9 183 k $28.0 k
2025 Q3 8 190 k $28.0 k
2025 Q2 7 182 k $28.0 k
2025 Q1 7 182 k $28.0 k
2024 Q4 7 182 k $28.0 k
2024 Q3 5 182 k $28.0 k
2024 Q2 7 187 k $28.0 k
2024 Q1 7 187 k $28.0 k
2023 Q4 6 187 k $130 k
2023 Q3 6 187 k $130 k
2023 Q2 7 187 k $130 k
2023 Q1 4 186 k $26.5 k
2022 Q4 4 190 k $0
2022 Q3 3 190 k $0
2022 Q2 3 190 k $0
2022 Q1 6 202 k $27.0 k
2021 Q4 5 205 k $0
2021 Q3 8 15.0 M $41.1 M
2021 Q2 8 15.3 M $37.9 M
2021 Q1 11 14.9 M $36.7 M
2020 Q4 35 42.2 M $107 M
2020 Q3 137 98.5 M $311 M
2020 Q2 141 96.0 M $281 M
2020 Q1 138 91.8 M $667 M
2019 Q4 157 100 M $325 M
2019 Q3 145 99.8 M $216 M
2019 Q2 158 107 M $338 M
2019 Q1 162 116 M $439 M
2018 Q4 158 122 M $352 M
2018 Q3 159 127 M $333 M
2018 Q2 169 128 M $300 M
2018 Q1 182 136 M $399 M
2017 Q4 193 142 M $389 M
2017 Q3 191 138 M $467 M
2017 Q2 178 130 M $322 M
2017 Q1 185 138 M $313 M
2016 Q4 205 133 M $281 M
2016 Q3 208 130 M $435 M
2016 Q2 210 126 M $395 M
2016 Q1 207 128 M $425 M
2015 Q4 218 136 M $482 M
2015 Q3 225 139 M $715 M
2015 Q2 215 147 M $946 M
2015 Q1 226 144 M $1.02 B
2014 Q4 237 160 M $1.24 B
2014 Q3 245 152 M $1.14 B
2014 Q2 237 161 M $1.56 B
2014 Q1 246 141 M $1.17 B